ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Public ClinicalTrials.gov record NCT04899518. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b/3, Randomized, Double-Masked, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease (OASIS-1)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Study Evaluating the Safety and Efficacy of Two Concentrations (0.4% and 1%) of ALY688 Ophthalmic Solution in Subjects with Dry Eye Disease
Study identification
- NCT ID
- NCT04899518
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 922 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 18, 2021
- Primary completion
- Mar 13, 2023
- Completion
- Mar 13, 2023
- Last update posted
- Mar 15, 2023
2021 – 2023
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Allysta Pharmaceuticals | Bellevue | Washington | 98004 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Dry Eye trials
Other public records listing Dry Eye. Sorted by last update posted; newest first. Not a recommendation.
- NCT07790211: BL-RX01-TFSTAB-1402 Recruiting
- NCT07705893: Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg Recruiting
- NCT07722624: A Single Center, Open-Label Study to Evaluate the Ability of the TearScience™ LipiView™ II Ocular Surface Interferometer and the Keratograph® 5M to Detect Tear Film Stability Utilizing Miebo® Active, not recruiting
- NCT07155070: Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK Recruiting
- NCT07659626: Long-term Effects of Acoltremon vs. Control in Dry Eye Disease Not yet recruiting
- NCT07618364: The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04899518, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 15, 2023 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04899518 live on ClinicalTrials.gov.